Please login to the form below

Not currently logged in

Amgen’s Joseph Turgeon joins Spectrum as SVP sales and commercial operations

Joins fellow former Amgen employee Ken Keller

Spectrum Pharmaceuticals has appointed former Amgen executive Joseph Turgeon to senior VP sales and commercial operations.

In his new role, Turgeon will have responsibility for the commercialisation and sales of Spectrum's complete portfolio, which includes cancer treatments Fusilev (levoleucovorin), Folotyn (pralatrexate injection) and Zevalin (ibritumomab tiuxetan).

Turgeon has strong pedigree in the oncology market, having most recently served as VP sales, oncology at Amgen, where he led the launch of four new drugs and oversaw an increase in annual revenue from $2bn to more than $6bn.

He is the second major figure to move from Amgen to Spectrum in recent months following the appointment of Ken Keller as chief operating officer in September this year.

”The addition of Mr Turgeon following appointment of Mr Keller earlier this year is part of a planned strategy for expedited growth of Spectrum Pharmaceuticals,” Rajesh Shrotriya, chair, president and CEO of Spectrum Pharmaceuticals.

“With three anticancer drugs on the market now bringing nearly $300m in pro forma revenue and nearly ten drugs in clinical development, we are committed to strong growth in the next five years.”

In addition to Turgeon's appointment, Spectrum also announced that the company's chief commercial officer Jim Shields is to retire due to health reasons. He will continue to serve Spectrum in an advisory role.

31st October 2012

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

THE SCIENCE BEHIND CREATIVE RESULTS When science meets art there's chemistry. We simply add passion, positivity and a human warmth....

Latest intelligence

The Journey to excellence
Over the last 20 years much has changed in healthcare delivery. The autonomy of choice of healthcare practitioners has been constrained as individual healthcare systems come to terms with increasing...
Increasing patient engagement through storytelling
Patient engagement in healthcare has long been considered the ‘holy grail’; it supports the successful adoption of medication by both payers and patients....
Powering behaviour change with human insights
Understanding human behaviour is a powerful underlying principle that we, as marketers, need to understand to improve patient outcomes. Human insights should be the cornerstone of any communication strategy.......